Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot cure insomnia in breast cancer survivors?

NCT ID NCT06392789

Symptom relief Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a text-message chatbot called Cecebot that combines sleep therapy and activity tips to help breast cancer survivors with insomnia. 60 women with stage I-III breast cancer and poor sleep used the chatbot for 6 weeks. The goal was to see if it was easy to stick with and if it improved sleep and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cecebot (a text-message-based conversational agent combining cognitive behavioral therapy for insomnia and physical activity strategies)
What this could lead to
If it works, this could offer a convenient, non-drug way to improve sleep and quality of life for breast cancer survivors.
What could go wrong
This is a small, early-stage trial with only 60 participants. The intervention is behavioral, so results may vary widely, and long-term benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Oct 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 80 years * Prior diagnosis of stage I-III invasive breast cancer * Female gender * Clinically significant insomnia symptoms, defined as a Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 8 T-score of 55 or greater * Insomnia complaints lasting ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating ability to perform activities of daily living * Own a smartphone with Internet connectivity * Willing and able to complete the intervention with personal smartphone * Proficient in speaking and reading English * Completed breast cancer treatment within past 5 years Exclusion Criteria: * Prior diagnosis of restless leg syndrome, periodic leg movement disorder, narcolepsy, or rapid eye movement (REM) behavior disorder * Current sleep apnea (treated or untreated) * Current shiftwork * Actively receiving chemotherapy or radiation (endocrine therapy permitted) * Previously received CBTi therapy with a professional therapist * Contraindications to CBTi including: * Active psychosis * Uncontrolled bipolar disorder * Severe depression * Active substance use disorder (moderate or greater severity) * Use of prescribed sleep medication \> 3 times per week * Previously participated in user testing of the study intervention (Cecebot) * Unwilling or unable to complete study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anatomic stage I breast cancer ajcc V8 Anatomic stage II breast cancer ajcc V8 Anatomic stage III breast cancer ajcc V8 Insomnia

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.